Related Experiment Videos
Coronary artery disease can be prevented by antihypertensive therapy: experiences from the MAPHY Study
J Tuomilehto1, J Wikstrand, I Warnold
1Department of Epidemiology, National Public Health Institute, Helsinki, Finland.
Insights
Metoprolol significantly reduced coronary artery disease (CAD) events compared to thiazide diuretics in hypertensive men. This suggests non-blood pressure-related mechanisms contribute to metoprolol
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Hypertension is a major risk factor for cardiovascular diseases.
- Primary prevention strategies aim to reduce the incidence of coronary artery disease (CAD).
- Comparative effectiveness of different antihypertensive drug classes requires ongoing investigation.
Purpose of the Study:
- To compare the efficacy of metoprolol versus thiazide diuretics in preventing CAD events.
- To investigate the role of initial treatment choice in primary prevention for hypertensive men.
- To explore potential mechanisms beyond blood pressure reduction in CAD prevention.
Main Methods:
- Randomized primary prevention study involving 3,234 hypertensive men aged 40-64 years.
- Follow-up duration of 15,730 patient-years.
- Comparison of CAD event incidence between metoprolol and thiazide diuretic treatment groups.
Main Results:
- Significantly lower incidence of CAD events in the metoprolol group (111) compared to the diuretic group (144) (p = 0.001).
- Stroke mortality was significantly lower with metoprolol, though overall stroke incidence was similar.
- Blood pressure control was comparable between groups, indicating CAD event differences are not solely due to BP reduction.
Conclusions:
- Metoprolol demonstrates superior efficacy in preventing coronary artery disease events compared to thiazide diuretics in hypertensive men.
- The cardioprotective effects of metoprolol may involve mechanisms independent of blood pressure lowering.
- Further research is warranted to elucidate the specific non-hemodynamic pathways involved in metoprolol's benefit.
Abstract:
The present randomized primary prevention study in hypertensive men aged 40-64 years (n = 3,234) was aimed at investigating whether metoprolol given as initial treatment would prevent coronary artery disease (CAD) better than thiazide diuretics. Two hundred fifty-five patients had a definite CAD event during the 15,730 patient-years of follow-up; 25% of these events were fatal, and 38% were definite acute myocardial infarctions. The incidence of CAD was significantly lower during follow-up in patients randomized to metoprolol than in patients randomized to diuretics: 111 vs. 144 cases (p = 0.001). Stroke mortality was significantly lower in the metoprolol group than in the diuretic group, but the overall stroke incidence was similar in the two treatment groups. A majority of events occurred among smokers in both treatment groups although only one-third of patients were smokers at baseline. Blood pressure (BP) control was similar in the two treatment groups; therefore, the difference between the groups in CAD events is mediated via mechanisms other than the BP-reducing effect of metoprolol.